LOGIN  |  REGISTER
Viking Therapeutics
Assertio

908 Devices to Report First Quarter Financial Results on May 9, 2023

April 25, 2023 | Last Trade: US$2.39 0.01 0.42

BOSTON / Apr 25, 2023 / Business Wire / 908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2023 before market open on Tuesday, May 9, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB